Circulating ACE2 activity correlates with cardiovascular disease development

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 17, Issue 4, 2016, Pages

  Úri, Katalin ^a   Fagyas, Miklós ^a   Kertész, Attila ^a   Borbély, Attila ^a   Jenei, Csaba ^a   Bene, Orsolya ^a   Csanádi, Zoltán ^a   Paulus, Walter J ^b   Édes, István ^a   Papp, Zoltán ^a   Tóth, Attila ^a   Lizanecz, Erzsébet ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin converting enzyme 2; biomarker; diastolic heart failure; hypertension; renin angiotensin aldosterone system; systolic heart failure

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DIASTOLE; ENZYMOLOGY; FEMALE; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; SYSTOLE;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIASTOLE; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROGNOSIS; ROC CURVE; SYSTOLE;

EID: 85018659977     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320316668435     Document Type: Article

References (37)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991; 121: 1244–1263
2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591–603
3. McMurray JJ, Adamopoulos S, Anker SD. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803–869
4. Ho KK, Pinsky JL, Kannel WB. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A–13A
5. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–2467
6. Cleland JG, Tendera M, Adamus J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345
7. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: An inconvenient truth! J Am Coll Cardiol 2010; 55: 526–537
8. Shahin Y, Khan JA, Samuel N. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomised controlled trials. Atherosclerosis 2011; 216: 7–16
9. Fagyas M, Uri K, Siket IM. New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: Endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One 2014; 9: e87843
10. Fagyas M, Uri K, Siket IM. New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: Albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One 2014; 9: e87844
11. Fagyas M, Uri K, Siket IM. New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: Endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. PLoS One 2014; 9: e93719
12. Uri K, Fagyas M, Manyine Siket I. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One 2014; 9: e87845
13. Paulus WJ, Tschope C, Sanderson JE. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550
14. Mancia G, Fagard R, Narkiewicz K. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357
15. Vickers C, Hales P, Kaushik V. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838–14843
16. Epelman S, Tang WH, Chen SY. Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008; 52: 750–754
17. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol 2013; 40: 551–559
18. Mozaffarian D, Benjamin EJ, Go AS. Heart disease and stroke statistics – 2015 update: A report from the American Heart Association. Circulation 2015; 131: e29–e322
19. Epelman S, Shrestha K, Troughton RW. Soluble angiotensin-converting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes. J Card Fail 2009; 15: 565–571
20. Patel SK, Velkoska E, Freeman M. From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol 2014; 5: 227
21. Cheng JM, Akkerhuis KM, Battes LC. Biomarkers of heart failure with normal ejection fraction: A systematic review. Eur J Heart Fail 2013; 15: 1350–1362
22. Anguiano L, Riera M, Pascual J. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol Dial Transplant 2015; 30: 1176–1185
23. Wang J, Li N, Gao F. Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2015; 16: 553–558
24. Patel VB, Clarke N, Wang Z. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J Mol Cell Cardiol 2014; 66: 167–176
25. Trojanowicz B, Ulrich C, Kohler F. Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. Nephrol Dial Transplant. Epub ahead of print 24 May 2016. DOI: 10.1093/ndt/gfw206
26. Julius S, Nesbitt SD, Egan BM. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697
27. Braunwald E, Domanski MJ, Fowler SE. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068
28. Simoons ML, Vos J, de Feyter PJ. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Eur Heart J 1998; 19(Suppl J): J56–J60
29. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041
30. Cowley AJ, Stainer K, Wynne RD. Comparison of the effects of captopril and enoximone in patients with severe heart failure: A placebo controlled double-blind study. Int J Cardiol 1989; 24: 311–316
31. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–1435
32. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
33. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450–1456
34. Packer M, Poole-Wilson PA, Armstrong PW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312–2318
35. Yamamoto K. beta-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. J Cardiol 2015; 66: 189–194
36. Senni M, Paulus WJ, Gavazzi A. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797–2815
37. Yusuf S, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777–781